Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $8.6 million.

  • Harvard Bioscience's Cost of Revenue fell 689.84% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.6 million, marking a year-over-year decrease of 745.35%. This contributed to the annual value of $39.4 million for FY2024, which is 1474.7% down from last year.
  • Per Harvard Bioscience's latest filing, its Cost of Revenue stood at $8.6 million for Q3 2025, which was down 689.84% from $8.9 million recorded in Q2 2025.
  • Harvard Bioscience's Cost of Revenue's 5-year high stood at $14.8 million during Q3 2022, with a 5-year trough of $8.6 million in Q3 2025.
  • Its 5-year average for Cost of Revenue is $11.4 million, with a median of $11.6 million in 2023.
  • In the last 5 years, Harvard Bioscience's Cost of Revenue surged by 3588.66% in 2021 and then tumbled by 2789.15% in 2023.
  • Quarter analysis of 5 years shows Harvard Bioscience's Cost of Revenue stood at $13.5 million in 2021, then fell by 6.68% to $12.6 million in 2022, then dropped by 6.08% to $11.8 million in 2023, then dropped by 10.85% to $10.5 million in 2024, then dropped by 18.73% to $8.6 million in 2025.
  • Its Cost of Revenue stands at $8.6 million for Q3 2025, versus $8.9 million for Q2 2025 and $9.6 million for Q1 2025.